Received Aug 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 4ZC23 | IM |
Subcutaneous injection formulation administered intramuscularly; This non-serious case was reported by a nurse via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 7-year-old female patient who received MMR (Priorix) (batch number 4ZC23, expiry date 01-SEP-2025) for prophylaxis. Previously administered products included Priorix (patient received 1st dose on unknown date). On 18-JUL-2025, the patient received the 2nd dose of Priorix (intramuscular). On 18-JUL-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Subcutaneous injection formulation administered intramuscularly). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 23-JUL-2025 Other HCP informed that a Priorix dose was given by the intramuscular route instead of subcutaneous one to a 7-year-old female patient, which led to subcutaneous injection formulation administered by other route. Vaccine was administered on 18 July 2025 as second dose. She wanted to know how to proceed after this incident.